HK1198442A1 - 吡唑並嘧啶衍生物、其製備方法及其治療用途 - Google Patents

吡唑並嘧啶衍生物、其製備方法及其治療用途

Info

Publication number
HK1198442A1
HK1198442A1 HK14111927A HK14111927A HK1198442A1 HK 1198442 A1 HK1198442 A1 HK 1198442A1 HK 14111927 A HK14111927 A HK 14111927A HK 14111927 A HK14111927 A HK 14111927A HK 1198442 A1 HK1198442 A1 HK 1198442A1
Authority
HK
Hong Kong
Prior art keywords
preparation process
therapeutic use
process therefor
pyrazolopyridine derivatives
pyrazolopyridine
Prior art date
Application number
HK14111927A
Other languages
English (en)
Inventor
Chantal Alcouffe
Kirsten Bjegarde
Jacques Mauger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1198442A1 publication Critical patent/HK1198442A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK14111927A 2011-12-14 2014-11-26 吡唑並嘧啶衍生物、其製備方法及其治療用途 HK1198442A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1161589A FR2984325A1 (fr) 2011-12-14 2011-12-14 Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
PCT/EP2012/075328 WO2013087744A1 (en) 2011-12-14 2012-12-13 Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof

Publications (1)

Publication Number Publication Date
HK1198442A1 true HK1198442A1 (zh) 2015-04-24

Family

ID=47458918

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14111927A HK1198442A1 (zh) 2011-12-14 2014-11-26 吡唑並嘧啶衍生物、其製備方法及其治療用途

Country Status (23)

Country Link
US (2) US20140350006A1 (zh)
EP (1) EP2791137B1 (zh)
JP (2) JP6214551B2 (zh)
KR (1) KR102012058B1 (zh)
CN (2) CN104114555B (zh)
AU (1) AU2012351712B2 (zh)
BR (1) BR112014014452A2 (zh)
CA (1) CA2857749A1 (zh)
CL (1) CL2014001539A1 (zh)
CO (1) CO7000778A2 (zh)
DK (1) DK2791137T3 (zh)
EA (1) EA027421B1 (zh)
ES (1) ES2719444T3 (zh)
FR (1) FR2984325A1 (zh)
HK (1) HK1198442A1 (zh)
IL (1) IL232906A (zh)
MA (1) MA35841B1 (zh)
MX (1) MX358422B (zh)
PH (1) PH12014501258A1 (zh)
PL (1) PL2791137T3 (zh)
PT (1) PT2791137T (zh)
SG (2) SG10201510204QA (zh)
WO (1) WO2013087744A1 (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
SG11201505488XA (en) 2013-01-16 2015-08-28 Inserm Inst Nat De La Santé Et De La Rech Médicale A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
JP6325078B2 (ja) 2013-03-15 2018-05-16 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． ヘテロ環式化合物およびその使用
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
KR20160021134A (ko) * 2013-06-14 2016-02-24 사노피 방광암 치료용 피라졸로피리딘 유도체
CN106660997B (zh) 2014-08-18 2019-05-21 卫材R&D管理有限公司 单环吡啶衍生物的盐及其晶体
WO2017053604A1 (en) * 2015-09-23 2017-03-30 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
HUE058734T2 (hu) 2016-07-07 2022-09-28 Pfizer Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
EP3752150A1 (en) * 2018-02-16 2020-12-23 UCB Biopharma SRL Pharmaceutical 6,5 heterobicyclic ring derivatives
CA3091153A1 (en) 2018-03-28 2019-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
CN108774224B (zh) * 2018-04-23 2020-10-30 浙江大学 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用
CN110833556A (zh) * 2018-08-15 2020-02-25 广西梧州制药（集团）股份有限公司 吡唑并嘧啶衍生物在治疗肝纤维化的用途
WO2020178316A1 (en) * 2019-03-05 2020-09-10 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. 5- or 7-azaindazoles as beta-lactamase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
MX2007014327A (es) * 2005-05-16 2008-02-11 Irm Llc Derivados de pirrolopiridina como inhibidores de cinasa de proteina.
US7541367B2 (en) * 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
FR2889526B1 (fr) * 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
BRPI0716477A2 (pt) * 2006-09-06 2014-03-18 Hoffmann La Roche Derivados heteroarila como inibidores de quinase protéica
KR20090031122A (ko) * 2007-09-21 2009-03-25 주식회사 중외제약 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물
NZ585434A (en) * 2007-11-30 2012-06-29 Pfizer Ltd Novel glucocorticoid receptor agonists
WO2010078427A1 (en) * 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
FR2951172B1 (fr) * 2009-10-13 2014-09-26 Pf Medicament Derives pyrazolopyridines en tant qu'agent anticancereux
JP5822844B2 (ja) * 2009-12-21 2015-11-24 サミュメッド リミテッド ライアビリティ カンパニー １Ｈ−ピラゾロ［３，４−ｂ］ピリジンおよびその治療的使用
WO2012019954A1 (en) * 2010-08-12 2012-02-16 Evotec (Uk) Ltd. Pyrazolopyridine compounds as pde10a inhibitors
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique

Also Published As

Publication number Publication date
PH12014501258A1 (en) 2014-09-08
EP2791137B1 (en) 2019-01-23
PT2791137T (pt) 2019-05-08
SG11201402851TA (en) 2014-07-30
WO2013087744A1 (en) 2013-06-20
MX2014007168A (es) 2015-02-10
CN106317056B (zh) 2020-06-23
JP6214551B2 (ja) 2017-10-18
MA35841B1 (fr) 2014-12-01
IL232906A (en) 2017-12-31
CN106317056A (zh) 2017-01-11
AU2012351712B2 (en) 2017-08-31
DK2791137T3 (en) 2019-04-23
JP2017206544A (ja) 2017-11-24
EA027421B1 (ru) 2017-07-31
US20140350006A1 (en) 2014-11-27
BR112014014452A2 (pt) 2017-06-13
KR102012058B1 (ko) 2019-08-19
EP2791137A1 (en) 2014-10-22
US20170231998A1 (en) 2017-08-17
ES2719444T3 (es) 2019-07-10
PL2791137T3 (pl) 2019-07-31
CN104114555B (zh) 2017-09-01
CA2857749A1 (en) 2013-06-20
MX358422B (es) 2018-08-20
CO7000778A2 (es) 2014-07-21
AU2012351712A1 (en) 2014-07-10
IL232906A0 (en) 2014-08-03
KR20140105551A (ko) 2014-09-01
EA201491149A1 (ru) 2014-11-28
CL2014001539A1 (es) 2014-10-17
FR2984325A1 (fr) 2013-06-21
JP2015500318A (ja) 2015-01-05
SG10201510204QA (en) 2016-01-28
CN104114555A (zh) 2014-10-22

Similar Documents

Publication Publication Date Title
HK1198442A1 (zh) 吡唑並嘧啶衍生物、其製備方法及其治療用途
IL231386A0 (en) Pyrazoloquinolinone derivatives, their preparation and medical use
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ZA201300100B (en) Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
EP2763998A4 (en) TRI-HETEROCYCLIC DERIVATIVES, MANUFACTURING METHOD AND USES THEREOF
IL231444A (en) Aniline derivatives, their preparation and their medical application
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL227711A0 (en) Phenyl-isoxazole history and their preparation process
IL233238A0 (en) Sulphonylaminopyrrolidinone derivatives, their preparation and therapeutic use
EP2865666A4 (en) HEXAHYDROPENTALENE DERIVATIVES, METHOD OF MANUFACTURE AND USE IN MEDICINE
EP2752419A4 (en) SPIROBENZYLAMINE-PHOSPHINE, ITS PREPARATION METHOD AND USE
EP2697239A4 (en) N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
HK1209127A1 (zh) 大環內酯衍生物、其製備及其治療用途
IL226388A0 (en) New indolizine derivatives, their preparation and medical use
IL220859A0 (en) Alkyl-heterocycle-carbamate derivatives, their preparation and therapeutic application
PL395184A1 (pl) Nowe pochodne benzimidazolu, sposób wytwarzania i zastosowanie pochodnych benzimidazolu
GB201112578D0 (en) Pharmaceutical preparation and use
PL395175A1 (pl) Nowe pochodne dekstrometorfanu i sposób ich wytwarzania